Exchange: LSE | Sector: Healthcare | Industry: Medical Equipment Services
Q1 2025
Published: Nov 1, 2024
Earnings Highlights
Revenue of $52.28B down 4.3% year-over-year
EPS of $1.70 increased by 8% from previous year
Gross margin of 3.6%
Net income of 416.00M
"N/A" - N/A
Cardinal Health Inc (0HTG.L) QQ1 2025 Results Analysis: Revenue Downbeat with Margins Stabilizing Yet Cash Flow Under Pressure
Executive Summary
Cardinal Health reported QQ1 2025 revenue of $52.28 billion, a year-over-year decline of 4.34% and a quarter-over-quarter drop of 12.45%. The quarter featured thin gross margins (approximately 3.64%) with operating income of $568 million and net income of $416 million, yielding an EPS of $1.71 (diluted $1.70). EBITDA stood at $755 million, signaling earnings before non-cash and financing effects remained positive, but profitability remains pressured by a lean margin profile in a highly competitive distribution landscape.
The company generated negative free cash flow of about $1.737 billion and an operating cash flow of approximately $-1.647 billion, driven primarily by a sizable working capital swing (notably large payables outflow and inventory and receivables movements). Cash and equivalents totaled roughly $2.867 billion at period end, while total assets were $43.06 billion against liabilities of $46.34 billion, yielding negative reported equity (~$3.28 billion) and a leveraged balance sheet by traditional equity-based metrics. Liquidity is tight (current ratio ~0.95; quick ratio ~0.50), underscoring balance sheet fragility amid ongoing macro/operational headwinds.
Management commentary in this dataset is not provided, so the analysis relies on disclosed financials and typical sector dynamics. Investors should monitor working capital normalization, continued cost containment, and any strategic actions to restore cash generation and balance sheet stability.
Note: No earnings call transcript is provided in the dataset. Consequently, no verbatim management quotes or theme-based quotes could be extracted. The forward-looking assessment below integrates typical management focus areas observed in the sector and the disclosed QQ1 2025 metrics.
N/A
â N/A
N/A
â N/A
Forward Guidance
No formal forward guidance is included in the supplied dataset for QQ1 2025. The analysis therefore relies on reported results and common near-term priorities observed in the healthcare distribution sector. Key considerations for guidance likelihood include: (i) stabilization of gross margins around the mid-3% to low-4% range as pricing pressures and mix evolve; (ii) working capital normalization to restore operating cash flow; (iii) cash flow optimization via reducing non-core expenditures or optimizing inventory and payables; (iv) potential strategic actions (M&A, portfolio refinement, or divestitures) that could bolster liquidity. Investors should monitor management commentary in subsequent filings for explicit targets on margin expansion, capital allocation, and debt reduction.
Competitive Position
Company
Gross Margin
Operating Margin
Return on Equity
P/E Ratio
0HTG.L Focus
3.64%
1.07%
-12.70%
16.13%
0HWH.L
34.40%
17.70%
6.33%
36.63%
0R09.L
72.40%
-27.50%
1.26%
-17.84%
0QYK.L
42.30%
15.80%
-20.20%
30.27%
Gross Profit Margin
Operating Profit Margin
Return on Equity
P/E Ratio Comparison
Investment Outlook
Base-case: modest revenue stability with gradual margin improvement and a return to positive cash flow contingent on working capital normalization and continued efficiency gains. Valuation remains modestly attractive on a price-to-sales basis (~0.513x) but is overshadowed by a fragile balance sheet and near-term cash flow pressure. Investors should require visibility on cash flow normalization, debt management, and sustainable margin expansion before committing to a more constructive stance.
Upside scenario: successful margin expansion toward the mid-4% to 5% range, meaningful working capital improvement, and a path to positive free cash flow within the next 4â8 quarters. Positive catalysts include price/mix optimization, portfolio refinements, and potential strategic actions that unlock scale and efficiency.
Downside scenario: continued margin compression, further cash-flow deterioration due to working capital headwinds, or strategic missteps that fail to address liquidity and equity concerns, increasing default risk perceptions. In such a scenario, the stock could underperform peers with stronger balance sheets and cash flow profiles.
Recommendation: Given the current liquidity constraints and negative equity, investors should approach Cardinal Health with a balanced, risk-aware stance. The stock may appeal to value-focused investors if a clear plan emerges to normalize working capital and delever the balance sheet, while growth-oriented investors may require a stronger bridge to sustainable FCF and a credible path to equity restoration. Key factors to monitor include: (1) working capital normalization trajectory (receivables, payables, and inventory dynamics), (2) any announced strategic actions or cost-savings programs, (3) quarterly cadence of EBITDA and cash conversion improvements, and (4) updates to forward guidance or medium-term financial targets in subsequent filings.
Key Investment Factors
Growth Potential
Growth potential centers on (i) continued scale in Cardinal Health's two segments (Pharmaceutical and Medical), (ii) optimization of working capital and supply chain efficiencies, (iii) expanding sterile and procedure kits offerings and home health solutions, and (iv) potential acquisitions or partnerships to drive share gains and cost synergies in distribution and logistics.
Profitability Risk
Key risks include persistently thin gross margins under pricing pressure, negative free cash flow and leverage constraints, potential further working capital deterioration, regulatory and reimbursement environment changes, competition driving pricing pressure from major distributors (MCK, ABC), and currency/foreign exposure given the London listing.
Financial Position
The balance sheet shows total assets of $43.06B against liabilities of $46.34B and negative equity of approximately -$3.28B, signaling solvency and structural equity challenges. Current ratio at 0.949 indicates liquidity pressure, while net debt of roughly $2.30B suggests a leveraged position relative to cash generation. While the company holds cash of ~$2.87B, the negative operating cash flow and negative free cash flow indicate fragility in cash generation without near-term improvements in working capital or profitability.
SWOT Analysis
Strengths
Extensive, diversified healthcare distribution network across US, Canada, Europe, and international markets.
Two-segment portfolio (Pharmaceutical and Medical) providing revenue diversification and cross-selling opportunities.
Healthy scale with large cash balance that can support liquidity strategies and selective strategic actions.
Weaknesses
Negative equity on the balance sheet (-$3.28B) indicating capitalization challenges.
Liquidity headwinds (current ratio 0.949; quick ratio 0.498) and negative free cash flow in QQ1 2025.
Thin gross margins (~3.64%) and a lean profitability profile, making the business susceptible to margin compression.
Material working capital fluctuations (significant payables contraction and inventory/receivables movements) depressing operating cash flow.
Opportunities
Optimization of working capital and supply chain efficiency to restore cash flow generation.
Growth in sterile/kit assembly, home health, and value-added services that can improve margin mix.
Potential strategic actions (e.g., select acquisitions, portfolio refinement) to bolster scale and operating leverage.
Continued adoption of digital and data-driven logistics to reduce costs and improve accuracy in a competitive distribution market.
Threats
Intense competition from large distributors (e.g., McKesson, AmerisourceBergen) putting pressure on pricing and margins.
Regulatory and reimbursement dynamics in healthcare that could impact distribution profitability.
Macro risks including currency volatility given London listing and cross-border operations.
Ongoing working-capital sensitivity and potential need for deleveraging amid negative equity.